{"title":"Sorafenib: advances in targeted therapy for renal cell carcinoma","authors":"Professor Robert E Hawkins, Dr Fiona C Thistlethwaite","doi":"10.1002/fps.12","DOIUrl":null,"url":null,"abstract":"<p>Sorafenib is the first dual action oral multi-kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 2","pages":"11-13"},"PeriodicalIF":0.0000,"publicationDate":"2008-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.12","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Sorafenib is the first dual action oral multi-kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.
索拉非尼:肾细胞癌靶向治疗的进展
索拉非尼是第一种双作用口服多激酶抑制剂，针对肿瘤细胞和肿瘤血管中的丝氨酸/苏氨酸和受体酪氨酸激酶。II期研究和目前最大的晚期肾细胞癌III期研究表明，索拉非尼将成为肾癌患者有价值的新疗法。版权所有©2006 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
